PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer.

ABSTRACT: The outlook for patients with pancreatic cancer remains dismal. Treatment options are limited and chemotherapy remains standard of care, leading to only modest survival benefits. Hence, there is a great need to further explore the mechanistic basis for the intrinsic therapeutic resistance of this disease, and to identify novel predictive biomarkers. RNA-binding motif protein 3 (RBM3) has emerged as a promising biomarker of disease severity and chemotherapy response in several types of cancer, including pancreatic cancer. The aim of this study was to unearth RBM3-regulated genes and proteins in pancreatic cancer cells in vitro, and to examine their expression and prognostic significance in human tumours. Next-generation RNA sequencing was applied to compare transcriptomes of MIAPaCa-2 cells

SUBMITTER: Olsson Hau S 

PROVIDER: S-EPMC8682941 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature